Pfizer

Please use landscape view or desktop screen to view the content.

Outline

Body Weight–Related Definitions Body Weight–Related Definitions
Effects of Body Weight on PK of Apixaban Effects of Body Weight on PK of Apixaban
Published Treatment Guideline Recommendations Guidance Recommendations for Overweight/Obese Patients
Baseline Weight in Apixaban Trials Baseline Weight in Apixaban Trials
Indications (NVAF, VTE and Hip/Knee Replacement)
Indications (NVAF, VTE and Hip/Knee Replacement)
NVAF Outline Arrow
ARISTOTLE
Study design | Primary efficacy results | Primary safety results
VTE Outline Arrow
AMP and AMP-EXT (DVT)
Study design | Primary efficacy results | Primary safety results
Hip/Knee Replacement Outline Arrow
ADVANCE 1, 2 and 3 (TKR, THR)
Study design | Primary efficacy results | Primary safety results
Pfizer

© 2023 Pfizer Inc. All rights reserved.

Menu Icon
Home Icon
  • Executive Summary Executive Summary Executive Summary
  • Body Weight–Related Definitions Body Weight–Related Definitions Body Weight–Related
    Definitions
  • Effects of Body Weight on Pharmacokinetics Effects of Body Weight on Pharmacokinetics Effects of Body Weight on Pharmacokinetics Menu Arrow Menu Arrow
    • Healthy Volunteers Menu Arrow Menu Arrow
      • Study design
      • Pharmacokinetics
      • Apixaban conc. vs. time
        and vs. antiXa activity
    • NVAF
    • VTE
  • US Label – Apixaban Effects on Body Weight US Label – Apixaban Effects on Body Weight US Label – Apixaban Effects on Body Weight Menu Arrow Menu Arrow
    • Dosing Recommendations
  • Treatment Guideline Recommendations Treatment Guideline Recommendations Guidance Recommendations Menu Arrow Menu Arrow
    • 2021 ISTH SCC Guidance
    • Expert Consensus Panel
  • Baseline Weight in Pivotal studies Baseline Weight in Pivotal studies Baseline Weight
    in Pivotal studies
  • Studies by Indication Studies by Indication Studies by Indication Menu Arrow Menu Arrow
    • NVAF Menu Arrow Menu Arrow
      • NVAF study overview
      • Apixaban Randomized Controlled Clinical Trial Data
      • ARISTOTLE Weight Subgroup Analysis (post hoc) Hohnloser et al.
      • ARISTOTLE BMI Analysis (post hoc) Sandhu et al.
      • Real-World Data
      • ARISTOPHANES 2020 Menu Arrow Menu Arrow
        • Objective
        • Study design
        • Results
      • Deitelzweig VA and Medicare 2022
      • Briasoulis 2021
      • O'Kane 2022
      • Kushnir 2019
    • VTE Menu Arrow Menu Arrow
      • VTE study overview
      • Apixaban Randomized Clinical Trial Data
      • AMPLIFY
      • AMPLIFY Post hoc Analysis
      • AMP-EXT
      • Real-World Data
      • Cohen 2021 (BMI ≥ 30 kg/m2)
      • Perino 2021 (BMI ≥ 40 kg/m2 or ≥ 120 kg)
      • Crouch 2022 (BMI ≥ 40 kg/m2 or ≥ 120 kg)
      • Kushnir 2019 (BMI ≥ 40 kg/m2)
    • Hip/Knee Replacement Menu Arrow Menu Arrow
      • ADVANCE-1
      • ADVANCE-2
      • ADVANCE-3
      • ADVANCE-2 and ADVANCE-3 weight and BMI Subgroup Analysis.
  • Appendix Appendix Appendix Menu Arrow Menu Arrow
    • Limitations/Disclaimers
Pfizer
Tooltip Close

References

  1. CRE, carbapenem-resistant Enterobacterales; ESBL, extended-spectrum β-lactamase; KPC, Klebsiella pneumoniae carbapenemases; OXA, oxacillinase
  2. CRE, carbapenem-resistant Enterobacterales; ESBL, extended-spectrum β-lactamase; KPC, Klebsiella pneumoniae carbapenemases; OXA, oxacillinase